Condition
Hepatitis B Vaccines
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (2)
P 4 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03408730Phase 3CompletedPrimary
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
NCT03393754Phase 3CompletedPrimary
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
NCT02797782UnknownPrimary
Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt
NCT02898922Phase 4CompletedPrimary
Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China
Showing all 4 trials